AU2001280632A1 - CRF2 ligands in combination therapy - Google Patents
CRF2 ligands in combination therapyInfo
- Publication number
- AU2001280632A1 AU2001280632A1 AU2001280632A AU8063201A AU2001280632A1 AU 2001280632 A1 AU2001280632 A1 AU 2001280632A1 AU 2001280632 A AU2001280632 A AU 2001280632A AU 8063201 A AU8063201 A AU 8063201A AU 2001280632 A1 AU2001280632 A1 AU 2001280632A1
- Authority
- AU
- Australia
- Prior art keywords
- crf
- receptor
- crfi
- receptor ligand
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21939100P | 2000-07-19 | 2000-07-19 | |
US60219391 | 2000-07-19 | ||
PCT/US2001/022808 WO2002005749A2 (en) | 2000-07-19 | 2001-07-19 | Crf2 ligands in combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001280632A1 true AU2001280632A1 (en) | 2002-01-30 |
Family
ID=22819077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001280632A Abandoned AU2001280632A1 (en) | 2000-07-19 | 2001-07-19 | CRF2 ligands in combination therapy |
Country Status (20)
Country | Link |
---|---|
US (2) | US20020035083A1 (bg) |
EP (1) | EP1383460A2 (bg) |
JP (1) | JP2004513880A (bg) |
KR (1) | KR20040014926A (bg) |
CN (1) | CN1501976A (bg) |
AU (1) | AU2001280632A1 (bg) |
BG (1) | BG107364A (bg) |
BR (1) | BR0111937A (bg) |
CA (1) | CA2416986A1 (bg) |
CZ (1) | CZ2003159A3 (bg) |
EE (1) | EE200300025A (bg) |
HU (1) | HUP0301833A3 (bg) |
IL (1) | IL153264A0 (bg) |
IS (1) | IS6673A (bg) |
MX (1) | MXPA02012721A (bg) |
NO (1) | NO20030214L (bg) |
PL (1) | PL365955A1 (bg) |
RU (1) | RU2003104509A (bg) |
WO (1) | WO2002005749A2 (bg) |
ZA (1) | ZA200300088B (bg) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
JP2009528289A (ja) * | 2006-02-27 | 2009-08-06 | ミシャロウ、アレクサンダー | 対抗適応を誘発することにより神経伝達物質系を調節する方法 |
US9555032B2 (en) | 2007-06-13 | 2017-01-31 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
CN104231059B (zh) * | 2013-06-19 | 2016-12-28 | 深圳翰宇药业股份有限公司 | 一种多肽及其制备方法和用途 |
WO2018075973A2 (en) * | 2016-10-20 | 2018-04-26 | Cortene Inc. | Methods of treating diseases resulting from a maladapted stress response |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4605642A (en) * | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
US5063245A (en) * | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
JPH10501420A (ja) * | 1994-06-14 | 1998-02-10 | ニューロクライン バイオサイエンシズ,インコーポレイティド | 副腎皮質刺激ホルモン放出因子▲下2▼レセプター |
US5663292A (en) * | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
US6214797B1 (en) * | 1995-06-13 | 2001-04-10 | The Salk Institute For Biological Studies | Urocortin peptides, nucleic acid encoding same methods for using same |
US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
US5861398A (en) * | 1996-08-26 | 1999-01-19 | Alanex Corporation | Benzoperimidine-carboxylic acids and derivatives thereof |
GB9717087D0 (en) * | 1997-08-12 | 1997-10-15 | Ciba Geigy Ag | Improvements in or relating to organic compounds |
-
2001
- 2001-07-19 JP JP2002511684A patent/JP2004513880A/ja active Pending
- 2001-07-19 RU RU2003104509/14A patent/RU2003104509A/ru not_active Application Discontinuation
- 2001-07-19 CA CA002416986A patent/CA2416986A1/en not_active Abandoned
- 2001-07-19 WO PCT/US2001/022808 patent/WO2002005749A2/en not_active Application Discontinuation
- 2001-07-19 EP EP01959036A patent/EP1383460A2/en not_active Withdrawn
- 2001-07-19 CZ CZ2003159A patent/CZ2003159A3/cs unknown
- 2001-07-19 US US09/908,825 patent/US20020035083A1/en not_active Abandoned
- 2001-07-19 PL PL01365955A patent/PL365955A1/xx not_active Application Discontinuation
- 2001-07-19 EE EEP200300025A patent/EE200300025A/xx unknown
- 2001-07-19 BR BR0111937-0A patent/BR0111937A/pt not_active IP Right Cessation
- 2001-07-19 IL IL15326401A patent/IL153264A0/xx unknown
- 2001-07-19 HU HU0301833A patent/HUP0301833A3/hu unknown
- 2001-07-19 CN CNA01814084XA patent/CN1501976A/zh active Pending
- 2001-07-19 AU AU2001280632A patent/AU2001280632A1/en not_active Abandoned
- 2001-07-19 MX MXPA02012721A patent/MXPA02012721A/es unknown
- 2001-07-19 KR KR10-2003-7000716A patent/KR20040014926A/ko not_active Application Discontinuation
-
2002
- 2002-12-09 BG BG107364A patent/BG107364A/bg unknown
-
2003
- 2003-01-03 ZA ZA200300088A patent/ZA200300088B/en unknown
- 2003-01-08 IS IS6673A patent/IS6673A/is unknown
- 2003-01-16 NO NO20030214A patent/NO20030214L/no not_active Application Discontinuation
-
2004
- 2004-08-26 US US10/926,558 patent/US20050059627A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050059627A1 (en) | 2005-03-17 |
IS6673A (is) | 2003-01-08 |
IL153264A0 (en) | 2003-07-06 |
PL365955A1 (en) | 2005-01-24 |
NO20030214D0 (no) | 2003-01-16 |
EP1383460A2 (en) | 2004-01-28 |
NO20030214L (no) | 2003-01-16 |
KR20040014926A (ko) | 2004-02-18 |
US20020035083A1 (en) | 2002-03-21 |
CA2416986A1 (en) | 2002-01-24 |
JP2004513880A (ja) | 2004-05-13 |
ZA200300088B (en) | 2005-05-09 |
HUP0301833A3 (en) | 2005-12-28 |
HUP0301833A2 (hu) | 2003-09-29 |
CZ2003159A3 (cs) | 2004-02-18 |
MXPA02012721A (es) | 2003-04-25 |
BG107364A (bg) | 2003-07-31 |
BR0111937A (pt) | 2005-04-12 |
CN1501976A (zh) | 2004-06-02 |
EE200300025A (et) | 2005-04-15 |
WO2002005749A3 (en) | 2003-11-06 |
WO2002005749A2 (en) | 2002-01-24 |
RU2003104509A (ru) | 2004-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7662948B2 (en) | Antisense oligonucleotides against VR1 | |
JP6250078B2 (ja) | 真核細胞におけるエキソンスキッピングの誘導 | |
JP4777777B2 (ja) | mRNA前駆体のスプライシングを修飾するENA核酸医薬 | |
US6136603A (en) | Antisense modulation of interleukin-5 signal transduction | |
JP5981428B2 (ja) | 筋緊張性ジストロフィー・プロテインキナーゼ(dmpk)発現の調整 | |
JP2015518712A (ja) | Mecp2発現を調節するための組成物及び方法 | |
US6258790B1 (en) | Antisense modulation of integrin α4 expression | |
JP2015523853A (ja) | Atp2a2発現を調節するための組成物及び方法 | |
JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
JP2015518711A (ja) | Bdnf発現を調節するための組成物及び方法 | |
US20050148017A1 (en) | Antisense oligonucleotides against tenascin for the treating of vitiligo | |
US20040063655A1 (en) | Antisense modulation of transforming growth factor-beta expression | |
Ho et al. | Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS | |
US6399297B1 (en) | Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs) | |
US20020035083A1 (en) | CRF2 ligands in combination therapy | |
JPH11512601A (ja) | 修飾プロテインキナーゼa特異的オリゴヌクレオチドおよびその使用法 | |
CA2457131A1 (en) | Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof | |
Wright et al. | κ-Opioid receptor antisense oligonucleotide injected into rat hippocampus causes hypertension | |
WO2000042178A2 (en) | Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function | |
US20220370487A1 (en) | Compositions targeting sodium channel 1.6 | |
WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
EP1485117A2 (en) | Methods for therapeutic treatment of benign prostatic hypertrophy (bph) | |
CA3195722A1 (en) | Therapeutic compositions for treating pain via multiple targets |